Message from the CEO

I would like to introduce myself as Dr. Anthony Baxter, the Chief Executive Officer of Cyprotex Discovery Ltd.

I have over 25 years experience in management and research within the pharmaceutical, biotech chemistry service and instrumentation industries, mainly in the areas of drug discovery, medicinal chemistry and combinatorial chemistry. Before joining Cyprotex Discovery, I successfully held positions as the CSO of Oxford Asymmetry International prior to its merger with Evotec, as founding CEO of Argenta Discovery Ltd and as CEO of deltaDOT, which specializes in novel biomolecule detection systems. I have also held positions as Research Manager at Ciba UK Central Research Laboratories (1990-1994) where I managed Ciba blue-sky research interests and as Team Leader at Glaxo Group Research (1983-1990). I have been actively involved in assisting in the scientific success of the development of several marketed drugs and in the discovery of advanced clinical development candidates for Curis, Serono, GSK, Ciba and Argenta.

I am proud to be leading Cyprotex Discovery which is a unique company, offering many advantages over traditional CRO’s. The company was founded in 1999 and has established a loyal and varied customer base of over 200 partners ranging from small Biotechs to large Pharma. Our customers recognise that Cyprotex Discovery provides reliable, high quality data on their compounds with unrivalled customer support. We have passed stringent acceptance standards set by our customers - and we've proven our ability to generate high quality, accurate data day in, day out, at highly competitive prices.

In 2010, we introduced our new in vitro toxicology service (branded as Cyprotox). We feel that this has been a natural progression for Cyprotex Discovery as it follows our existing philosophy of generating data early to predict clinical outcome and reduce late stage failure. As well as the addition of 90 square metres of laboratory space we have invested in the latest technology of automated fluorescent imaging and cellular analysis with the purchase of a Thermo Scientific Cellomics Arrayscan VTI high content screening instrument.  This technology allows the measurement of multi-parametric indicators of cell toxicity and therefore different markers of toxicity can be investigated within the same sample and cell population which is a very valuable tool in drug discovery. By integrating Cyprotox with our existing expertise in ADME and PK screening and prediction (branded as Cyprotex), it provides us with a key advantage over many of our competitors and allows us to advise our customers on the link between pharmacokinetics and toxicity.

Within our Cyprotex ADME and pharmacokinetics brand, we have developed three main product areas, Cloe® Screen, Cloe® Select and Cloe® Predict. Our unique Cloe® Screen platform is based on state of the art robotics and a highly sophisticated customised information management system which dramatically reduces the cost and time in generating data whilst ensuring excellent reproducibility of data. All the main ADME assays are available under this service.

Cyprotex also offers support for later stage ADME assays and pharmacokinetic studies under our Cloe® Select banner. These services can be customised to specific customer requirements and enable support to be provided through the drug development stage.

In addition to the experimental screening business, we offer a range of predictive services and have extensive expertise in physiologically based pharmacokinetic (PBPK) and quantitative structure activity relationship (QSAR) modelling. Cyprotex have developed a novel software package, named Cloe® PK, to assist in the prediction of pharmacokinetics from in vitro ADME data. By combining both in vitro ADME screening with unique pharmacokinetic prediction systems Cyprotex sets itself apart from many of its competitors.

We pride ourselves in providing state of the art services for our customers and are investing heavily in customer driven requests for new assays and equipment.  In 2008, we purchased an Applied Biosystems Sciex QTRAP® 5500 LC-MS/MS. This is one of the most sensitive ion trap instruments within the industry and will enable us to introduce a superior bioanalytical service. We are also investing heavily on our website and the introduction of Cloe® Gateway will allow our customers to access our services online. Cyprotex Discovery are commited to extending our range of experimental assays in order to provide a ‘one stop shop’ for all our customer needs. Understanding the correlation between the in vitro data and the in vivo properties of a compound is critical and we are constantly investigating improved experimental methodology and predictive technology to enhance this relationship.

Cyprotex Discovery understands that sustainable growth is dependent on the in-house expertise and knowledge of our entire staff combined with an understanding of our customers ever changing needs. We are committed to continued development of our existing capabilities without losing the uniqueness of the services we offers.

I look forward to working with our past, current and future Life Science based customers in providing exceptional ADMET and pharmacokinetics services in a world leading drug discovery and development CRO.

Dr. Tony Baxter
CEO, Cyprotex Discovery Ltd